Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 4/20 | 0.38 |
| ▸ | CTSS | P25774 | 3/20 | 0.38 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 2/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5014045 | 1.00 | KLK5 (0.41) | KLK5TDP1MEN1KMT2AGAA | |
| SCHEMBL24130603 | 0.88 | KLK5 (0.41) | KLK5TDP1MEN1KMT2AGAA | |
| SCHEMBL24130607 | 0.87 | KLK5 (0.40) | KLK5TDP1MEN1KMT2AGAA | |
| SCHEMBL24130635 | 0.87 | KLK5 (0.40) | KLK5TDP1MEN1KMT2AGAA | |
| SCHEMBL16790408 | 0.86 | MEN1 (0.46) | TDP1MEN1KMT2AGAACTSK | |
| SCHEMBL16765446 | 0.86 | MEN1 (0.46) | TDP1MEN1KMT2AGAACTSK | |
| SCHEMBL18764728 | 0.85 | TDP1 (0.45) | KLK5TDP1MEN1KMT2AGAA | |
| SCHEMBL2668380 | 0.85 | CTSL (0.49) | TDP1MEN1KMT2AGAACTSK | |
| SCHEMBL3617926 | 0.84 | CYP1A2 (0.47) | KLK5CTSKCTSSCA12CA14 | |
| SCHEMBL313779 | 0.84 | CYP1A2 (0.47) | KLK5CTSKCTSSCA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116410145-A | Preparation method of MRTX849 intermediate | 上海泓博智源医药股份有限公司 | 2023-07-11 | — | — | CN | disclosed |
| WO-2016144665-A1 | METHOD FOR PREPARING LARGAZOLE ANALOGS AND USES THEREOF | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2016-09-15 | — | — | WO | disclosed |
| US-9186402-B2 | Method for preparing largazole analogs and uses thereof | Colorado State University Research University (US) | 2015-11-17 | — | — | US | disclosed |
| US-8513290-B2 | Method for preparing largazole analogs and uses thereof | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120264794-A1 | Method for Preparing Largazole Analogs and Uses Thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-8217076-B2 | Method for preparing largazole analogs and uses thereof | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-07-10 | — | — | US | disclosed |
| EP-1752455-B1 | Chemokine receptor binding heterocyclic compounds | ANORMED INC (CA) | 2010-11-10 | — | — | EP | disclosed |
| US-7807694-B2 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| US-20100029731-A1 | Method for preparing largazole analogs and uses thereof | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2010009334-A1 | METHOD FOR PREPARING LARGAZOLE ANALOGS AND USES THEREOF | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-01-21 | — | — | WO | disclosed |
| EP-2030981-A1 | Compounds for proteasome enzyme inhibition | Proteolix, Inc. (US) | 2009-03-04 | — | — | EP | disclosed |
| EP-1752455-A2 | Chemokine receptor binding heterocyclic compounds | ANORMED INC. (CA) | 2007-02-14 | — | — | EP | disclosed |
| US-20060252795-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2006-11-09 | — | — | US | disclosed |
| US-7091217-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED, INC. (CA) | 2006-08-15 | — | — | US | disclosed |
| EP-1317451-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC (CA) | 2006-08-09 | — | — | EP | disclosed |
| US-20040171638-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2004-09-02 | — | — | US | disclosed |
| US-6734191-B2 | PREFERABLY TERTIARY AMINES COMPRISING TETRAHYDROQUINOLINE AND BENZIMIDAZOLE; USE TREATING HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND FELINE IMMUNODEFICIENCY VIRUS (FIV) | ANORMED, INC. (CA) | 2004-05-11 | — | — | US | disclosed |
| US-20030028022-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2003-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029731-A1 | Method for preparing largazole analogs and uses thereof | CYP51A1, ADPRS, LPXN | KLK5 507/4885TDP1 1755/4885MEN1 578/4885 |
| US-20060252795-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR3, CCR2 | KLK5 3150/4885TDP1 4360/4885MEN1 4602/4885 |
| US-20040171638-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR3, CCR2 | KLK5 3150/4885TDP1 4360/4885MEN1 4602/4885 |
| US-20030028022-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR3, CCR2 | KLK5 3150/4885TDP1 4360/4885MEN1 4602/4885 |
| US-20120264794-A1 | Method for Preparing Largazole Analogs and Uses Thereof | CYP51A1, ADPRS, LPXN | KLK5 507/4885TDP1 1755/4885MEN1 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.